Related Experiment Video

Updated: Jun 11, 2025

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

6.1K

Safety of Prior Propranolol Therapy for Infantile Hemangioma

Iraj Hasan1, Zachary Zinn2

  • 1School of Medicine, West Virginia University, Morgantown, West Virginia, USA.

Pediatric Dermatology
|October 8, 2024
PubMed

Insights

Propranolol treatment for infantile hemangioma (IH) in infancy showed no increased risk of growth impairment, sleep disorders, learning disabilities, or diabetes mellitus up to age 17. This study confirms the safety of propranolol for IH patients long-term.

Area of Science:

  • Pediatric pharmacology
  • Dermatology
  • Clinical research

Background:

  • Propranolol is the standard treatment for infantile hemangioma (IH) since 2008.
  • Previous research explored short-term effects of infant propranolol therapy for IH.
  • Long-term adverse effects of propranolol for IH require further investigation.

Purpose of the Study:

  • To assess the long-term risk of specific adverse effects in children treated with propranolol for IH.
  • To evaluate the association between infant propranolol therapy for IH and later-life health outcomes.

Main Methods:

  • Retrospective cohort study using the TrinetX database.
  • Included children aged 10-17 years who received propranolol for IH in infancy.
  • Analyzed risks of growth impairment, sleep disorders, learning disabilities, and diabetes mellitus.

Main Results:

  • No statistically significant increased risk of growth impairment was observed.
  • No statistically significant increased risk of sleep disorders was observed.
  • No statistically significant increased risk of learning disabilities or diabetes mellitus was observed.

Conclusions:

  • Infant propranolol therapy for IH is not associated with increased long-term risks up to age 17.
  • Findings support the established safety profile of propranolol for infantile hemangioma treatment.
  • This study provides evidence for the continued safe use of propranolol in managing IH.

Keywords:
infantile hemangiomapropranololsafety

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
536
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
414
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
594
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
716
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K